AAPD Antibiotic Prophylaxis for Dental Patients at Risk for Infection (2026): which children get premedication, which drug, and where it hands off to the AHA

What it says#

The document's premise is restraint. Bacteremia is anticipated after invasive dental procedures, and prophylaxis exists to reduce or eliminate it in patients whose cardiac disease, immunosuppression or immunodeficiency compromises their ability to fight a simple infection. But randomized trials supporting prophylaxis are limited, especially in children, many recommendations rest on expert consensus, and one study the AAPD cites found 80% of preprocedural antibiotic prescriptions unnecessary because risk factors were not present. Antibiotic use breeds resistance and carries anaphylaxis risk, so the decision is made on an individual basis, stewardship is integral, and the AAPD says prevention of oral disease through home care and regular dental care is considered more important than prophylaxis.

For cardiac patients the AAPD reprints the American Heart Association's 2021 tables and defers to them. Prophylaxis is suggested only for dental procedures that involve manipulation of gingival tissues, the periapical region of teeth, or perforation of the oral mucosa, and only for patients with the highest risk of an adverse outcome from viridans group streptococcal endocarditis. Those conditions are: a prosthetic cardiac valve or material, including transcatheter valves, valve repair with annuloplasty rings or clips, and left ventricular assist devices or an implantable heart; previous, relapsed or recurrent endocarditis; and congenital heart disease that is unrepaired and cyanotic (including palliative shunts and conduits), completely repaired with prosthetic material or a device during the first six months after the procedure, repaired with residual defects at or adjacent to a prosthetic patch or device, or treated with a surgical or transcatheter pulmonary artery valve or conduit such as a Melody valve or Contegra conduit; plus cardiac transplant recipients who develop valvulopathy. Not suggested: implantable electronic devices such as pacemakers, septal defect closure devices once closure is complete, peripheral vascular grafts and patches including those for hemodialysis, coronary and other vascular stents, CNS ventriculoatrial shunts, vena cava filters and pledgets. Procedures that do not call for prophylaxis are anesthetic injections through noninfected tissue, radiographs, placement of removable prosthodontic or orthodontic appliances, adjustment of orthodontic appliances, placement of brackets, shedding of primary teeth and bleeding from trauma to the lips or oral mucosa. The AAPD adds that patients with a reported history of injection drug use, and patients with rheumatic heart disease with residual disease such as moderate or severe regurgitation or stenosis, may be considered at risk, with physician consultation to settle it.

The regimen table is a single dose 30 to 60 minutes before the procedure. Oral: amoxicillin, 2 g for adults and 50 mg/kg for children. Unable to take oral medication: ampicillin 2 g IM or IV (50 mg/kg for children), or cefazolin or ceftriaxone 1 g IM or IV (50 mg/kg). Allergic to penicillin or ampicillin, oral: cephalexin 2 g (50 mg/kg), or another first- or second-generation oral cephalosporin in equivalent dosing; azithromycin or clarithromycin 500 mg (15 mg/kg); or doxycycline 100 mg (2.2 mg/kg under 45 kg, 100 mg over 45 kg). Allergic and unable to take oral medication: cefazolin or ceftriaxone 1 g IM or IV (50 mg/kg). Cephalosporins are not used in anyone with a history of anaphylaxis, angioedema or urticaria with penicillin or ampicillin. Clindamycin is no longer recommended, which the AAPD attributes to frequent and significant adverse drug reactions from Clostridium difficile infection. Doxycycline is the alternative for patients who cannot tolerate a penicillin, cephalosporin or macrolide, and the AAPD notes that short-term use under 21 days has not been associated with tooth discoloration in children under 8. If the dose is missed it can be given up to 2 hours after the procedure; a different class is used if the patient is already on oral antibiotics or has an allergy; a patient on parenteral antimicrobials for endocarditis or another infection can continue the same antibiotic; and elective procedures should, if possible, be delayed 10 days after a short antibiotic course.

Beyond the heart, the AAPD's own lists take over. For compromised immunity, evidence does not support widespread prophylaxis, which is reserved for high-risk patients after physician consultation; the candidates named are immunosuppression with neutropenia, cancer chemotherapy, immunosuppressive or radiation therapy with an absolute neutrophil count under 1000/mm3, hematopoietic stem cell or solid organ transplantation, HIV with a polymorphonuclear leukocyte count under 500/mm3, severe combined immunodeficiency and neutrophil, complement or other primary immunodeficiencies with recurrent infections, autoimmune disease such as juvenile arthritis or lupus, functional or anatomic asplenia, chronic high-dose steroids, uncontrolled diabetes, medication-related osteonecrosis of the jaw and hemodialysis. For head and neck radiation, prophylaxis has been suggested to reduce osteoradionecrosis risk but the evidence in the absence of infection is weak. For prosthetic joints, prophylaxis is no longer recommended, with the ADA's 2015 management table reprinted. For hydrocephalus shunts, ventriculoatrial and ventriculoperitoneal shunts no longer call for prophylaxis, and the AHA found no evidence linking dental procedures to infections of cardiovascular implantable electronic devices or nonvalvular devices.

Who it applies to#

Pediatric dentists and any general dentist treating a child or adolescent with a heart condition, a compromised immune system, a shunt, a device or a joint replacement; the regimens carry adult doses too, so the same table works for the parent in the next chair. The AAPD's own scope statement is that the categorization should help practitioners identify children who may be at increased risk, that the list is not exhaustive, and that a syndrome or condition the practitioner does not recognize is a reason to discuss risk with the child's physician before any invasive procedure.

It is a best practice of a specialty academy, not a law, and it explicitly defers: to the AHA for cardiac conditions and regimens, to the ADA's 2015 guideline for prosthetic joints, and to the child's physician for immune compromise, indwelling vascular catheters or shunts, and implanted devices. Where a family, a cardiologist or an orthopedic surgeon wants prophylaxis the tables do not suggest, the AAPD reprints the AHA's answer: shared decision making, with the provider familiar enough with the 2021 statement to explain the risks and benefits.

What changed#

The AAPD first adopted prophylaxis recommendations in 1990 and last revised them in 2022 (Reference Manual 2022:500-506); the 2026 revision is built on the AHA's 2007 guideline, its 2015 pediatric endocarditis statement, its 2021 viridans group streptococcal statement, the ADA's 2015 prosthetic joint guideline and a ten-year PubMed search that identified 94 articles and kept 13. The direction of every change it reports is toward fewer prescriptions: clindamycin removed by the AHA in 2021 and doxycycline added as an alternative; prosthetic joints no longer covered, with the AAPD citing the ADA's 2015 guideline and a 2025 AAOS guideline summary; ventriculoatrial and ventriculoperitoneal shunts no longer covered; nonvalvular cardiovascular devices excluded on the AHA's finding of no evidence; and the emphasis moved to oral hygiene, because the AHA's key finding is that endocarditis is far more likely to follow the bacteremia of chewing and toothbrushing than a dental procedure. The reprinted AHA summary also suggests biannual dental examinations for at-risk patients when care is available.

Where the source is#

The link under the title is the AAPD's page for this best practice in The Reference Manual of Pediatric Dentistry, which carries the abstract and a Download PDF button; the PDF, ten pages headed Official But Unformatted with Latest Revision 2026, is at aapd.org/globalassets/media/policies_guidelines/bp_prophylaxis26.pdf and is what the tables above were read from. Its cardiac condition, procedure and regimen tables are reprinted with permission from the American Heart Association, copyright 2021 (Circulation 2021;143(20):e963-e978, with errata), and its prosthetic joint table from the ADA (JADA 2015;146(1):11-16); the AHA journal page refused automated access in this session, so its content is reported here as the AAPD reprints it. Page numbers for the 2026-2027 manual were pending at the time of reading.